Alacepril is a relatively novel angiotensin-converting enzyme inhibitor. Alacepril as treatment for MVD (mitral valve disease) is well tolerated in most dogs, and different conditions of cardiac loading may influence the effect of the drug. Alacepril is expected to improve the quality of life of dogs with early stage MVD[3]. Approximately 0.6-0.7 mM of alacepril inhibited 50% of the ROS production by BAL cells from COPD (chronic obstructive pulmonary disease) patients, whereas a slightly higher concentration (3 mM) of lisinopril, an ACE inhibitor not bearing an SH-group, was necessary to inhibit the production of ROS(reactive oxygen species)[4]. Alacepril significantly suppresses the augmented cardiovascular and sympathetic nervous responses to mental stress in patients with essential hypertension[5]. Alacepril was effective in essential hypertension both at rest and during exercise, suggesting that the antihypertensive effect during exercise might be related to the decrease in pressor hormones, especially in plasma angiotensin II[6]. Alacepril prevents the development of atherosclerosis by reducing vascular ACE (angiotensin-converting enzyme) activity in monkeys given a high-cholesterol diet[7].
搜索
